Program: Monday (25.10.2010)

08:30 – 10:00

Room: Großer Saal

Scientific Session Basic Research

  • Andreas Rosenwald
  • Margaret Shipp
  • Pathogenesis of HL

    • Ralf Küppers
  • cHL and Microenvironment

    • Randy Gascoyne
  • Rationale for Non-Genotoxic Treatment

    • Stephan Mathas
  • From High Dimensional Data to Disease Mechanisms – NOTCH Signaling in Hodgkin Lymphoma

    • Karl Köchert
  • The Role of miRNAs in Hodgkin Lymphoma

    • Anke van den Berg
  • Methylation Pro ling of Mediastinal Gray Zone Lymphoma Reveals a Distinctive Signature with Elements Shared by Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

    • Franziska Eberle

10:30 – 12:00

Room: Großer Saal

Scientific Session Early Stages

  • Anton Hagenbeek
  • Richard Hoppe
  • Actions Following the Interim Analysis of the EORTC/GELA/IIL Intergroup H10 Trial

    • John Raemaekers
  • Debate: Role of Radiotherapy in Early Favorable HL

    • George Canellos
    • Anton Hagenbeek
    • Joachim Yahalom
  • State of the Art and Future Perspectives

    • Andreas Engert
  • Early FDG-PET Scan Con rms Its Prognostic Impact Also in Localized Stage, ABVD Treated Hodgkin Lymphoma Patients

    • Luigi Rigacci
  • Involved Node Radiotherapy Signi cantly Reduces Lung, Breast and Thyroid Dose in Patients with Limited Stage Hodgkin Lymphoma

    • Belinda Campbell

10:30 – 12:00

Room: Kleiner Saal

Workshop Pediatric HL

  • Judith Landman-Parker
  • Cindy L. Schwartz
  • Early Response-Based HL Therapies of the COG

    • Cindy L. Schwartz
  • Update on EuroNet-PHL-C1 trial

    • Dieter Körholz
  • Hodgkin Lymphoma therapy in Central America

    • Pedro De Alarcon
  • Involved Level 3-D Based Target Volume Concepts for Pediatric Hodgkin Lymphoma

    • Lütgendorf-Caucig
  • Update on LPHL

    • Judith Landman-Parker
  • Panel Discussion

    • Louis S. Constine
    • Dieter Körholz
    • Judith Landman-Parker
    • Cindy L. Schwartz

12:00 – 14:00

Room: Großer Saal

Satellite Symposium State-of-the-Art and Future Approaches

  • Andreas Engert
  • Michael Hallek
  • Lunch

  • Hodgkin Lymphoma

    • Peter Borchmann
  • Chronic Lymphatic Leukemia

    • Michael Hallek
  • Follicular Lymphoma

    • Gilles Salles

14:00 – 15:30

Room: Großer Saal

Scientific Session Special Challenges in HL

  • Magnus Björkholm
  • Teodoro Chisesi
  • WS Report on Non-Western Countries

    • James Armitage
  • WS Report on HL Treatment of Adolescents

    • Joseph Connors
  • WS Report on NLPHL

    • Michele Ghielmini
  • Hodgkin Lymphoma and HIV Infection (HD- HIV): Prognostic Factors in 596 Patients (Pts) within the European Group for the Study of HIV and Tumours

    • Michele Spina
  • Feasibility and Ef cacy of ABVD in Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)

    • Boris Böll
  • Autologous Stem Cell Transplantation for Adolescents and Young Adults with Relapsed or Refractory Hodgkin Lymphoma

    • Michael Crump

16:00 – 17:30

Room: Großer Saal

Scientific Session Survivorship

  • Franco Cavalli
  • Volker Diehl
  • WS Report on Follow-Up Recommendations

    • John Raemaekers
  • Long-Term Outcome of Children and Adolescents

    • Kara Kelly
  • Quality of Life in HL

    • Peter Borchmann
  • A Comprehensive Prospective National Database to Enhance Breast Cancer (BC) Screening Services for Hodgkin Lymphoma (HL) Survivors Treated with Supradiaphragmatic Radiotherapy (SRT) in England

    • Sache Howell
  • A Prospective Study of Breast Magnetic Resonance Imaging (MRI) and Mammographic Screening in Long-Term Female Hodgkin Lymphoma (HL) Survivors

    • Andrea Ng
  • Coronary Artery Disease in Patients Treated for Hodgkin Lymphoma: Preliminary Results Using Computed Angiography Tomography

    • Theodore Girinsky

18:00 – 19:00

Room: Großer Saal

Satellite Symposium New Aspects of Lymphoma Therapy

  • Peter Borchmann
  • Robert Marcus
  • Mantle Cell Lymphoma – Quo Vadis?

    • Georg Heß
  • Follicular Lymphoma – Bortezomib in the Relapsed/Refractory Setting

    • Mathias Rummel


You a viewing the program of a past symposium. Click here to get back to the current conference.